Hinrichsen 2002.

Methods	Randomised clinical trial with two‐group design. Samlpe size calculation: unclear, not described. Intention‐to‐treat analysis: used.
Participants	Country: Germany. Number of participants randomly assigned: 72; 41 men and 31 women. All participants were treatment‐naive. All participants were infected with HCV genotype two and three. Inclusion and exclusion criteria: none stated.
Interventions	Participants were randomly assigned to two groups. Group 1: peginterferon alpha‐2b 100 µg with ribavirin 800 mg for 24 weeks (n = 36). Group 2: interferon alpha‐2b 3 MU with ribavirin 1000 mg to 1200 mg for 24 weeks (n = 36).
Outcomes	Primary outcomes were sustained and end of treatment virological responses. Other outcome reported is quality of life. Limit for hepatitis C virus RNA detection was 50 IU/mL.
Notes	The report is abstract; because the study has not been published yet, no data about inclusion and exclusion criteria are provided. Study author contacted for additional information, but no data obtained.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Comments: Method used to perform sequence generation is not mentioned.
Allocation concealment (selection bias)	Low risk	Comments: Allocation concealment is not mentioned.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Comments: Blinding is not mentioned.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: The trial seems to have addressed incomplete outcome data adequately.
Selective reporting (reporting bias)	Unclear risk	Comment: All clinically relevant and reasonably expected outcomes were reported.
Other bias	Low risk	Comment: The trial seems to be free of other sources of bias.